| Indication | ‒ Healing of all grades of erosive esophagitis (EE) ‒ Maintaining healing of EE ‒ Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) |
| Status | First- to File (FTF), Par received final approval on April 2017. |
| Product Advantages | ‒ FTF, 180-day market exclusivity right in the USA. ‒ settled with Takeda, and will launch in 2022. |
| Potential Market | The market value of branded drug is about $1 billion per year. Par, a commercialization partner of Handa, is expected to occupy a certain market share. |
?
R&D
Dexlansoprazole DR capsule-60mg
